How Cost-Effective Are New Drugs for Myasthenia Gravis? An ICER Review Weighs the Options

A new analysis from the Institute for Clinical and Economic Review said the evidence available to date shows moderate effectiveness of two newer drugs for myasthenia gravis—eculizumab and efgartigimod—but found their price exceedingly high and their use not cost-effective.